NASDAQ: EXELExelixis Inc Stock Ownership - Who owns Exelixis?
Insider buying vs selling
Have Exelixis Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Jack L. Wyszomierski | Director | 2025-06-03 | 7,535 | $43.09 | $324.68kSell |
| Sue Gail Eckhardt | Director | 2025-06-02 | 18,834 | $42.74 | $804.97kSell |
| Sue Gail Eckhardt | Director | 2025-06-02 | 4 | $43.67 | $174.68Sell |
| Tomas J. Heyman | Director | 2025-05-21 | 4,544 | $44.29 | $201.25kSell |
| Patrick J. Haley | EVP Commercial | 2025-05-20 | 34,387 | $44.06 | $1.52MSell |
| Amy C. Peterson | EVP Prod Dev Med Aff CMO | 2025-05-16 | 72,776 | $45.47 | $3.31MSell |
| George Poste | Director | 2025-05-16 | 20,634 | $45.99 | $948.96kSell |
| George Poste | Director | 2025-05-16 | 20,634 | $19.77 | $407.93kBuy |
| Christopher J. Senner | EVP and CFO | 2025-05-16 | 100,000 | $46.00 | $4.60MSell |
| Christopher J. Senner | EVP and CFO | 2025-05-16 | 100,000 | $18.80 | $1.88MBuy |
EXEL insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when EXEL insiders and whales buy or sell their stock.
EXEL Shareholders
What type of owners hold Exelixis Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Blackrock Inc | 11.13% | 30,356,918 | $1.26B | Institution |
| Vanguard Group Inc | 10.51% | 28,671,987 | $1.19B | Institution |
| Farallon Capital Management LLC | 8.26% | 22,533,500 | $937.17M | Institution |
| Renaissance Technologies LLC | 5.44% | 14,824,265 | $616.54M | Institution |
| State Street Corp | 4.32% | 11,789,612 | $490.33M | Institution |
| Lsv Asset Management | 2.99% | 8,161,338 | $339.43M | Institution |
| Fuller Thaler Asset Management Inc | 2.86% | 7,795,074 | $324.20M | Institution |
| Geode Capital Management LLC | 2.72% | 7,417,180 | $308.48M | Institution |
| Aqr Capital Management LLC | 2.53% | 6,893,889 | $286.72M | Institution |
| Invesco Ltd | 2.04% | 5,572,189 | $231.75M | Institution |
EXEL vs Biotech Stocks
Exelixis Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.